- Home
- UAL vs NTRA Comparison
UAL vs NTRA Comparison
Compare UAL & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- NTRA
- Stock Information
- Founded
- UAL 1934
- NTRA 2003
- Country
- UAL United States
- NTRA United States
- Employees
- UAL N/A
- NTRA N/A
- Industry
- UAL Air Freight/Delivery Services
- NTRA Medical Specialities
- Sector
- UAL Consumer Discretionary
- NTRA Health Care
- Exchange
- UAL Nasdaq
- NTRA Nasdaq
- Market Cap
- UAL 26.5B
- NTRA 21.7B
- IPO Year
- UAL N/A
- NTRA 2015
- Fundamental
- Price
- UAL $106.59
- NTRA $168.02
- Analyst Decision
- UAL Strong Buy
- NTRA Strong Buy
- Analyst Count
- UAL 15
- NTRA 16
- Target Price
- UAL $108.00
- NTRA $193.50
- AVG Volume (30 Days)
- UAL 4.8M
- NTRA 1.2M
- Earning Date
- UAL 10-14-2025
- NTRA 08-07-2025
- Dividend Yield
- UAL N/A
- NTRA N/A
- EPS Growth
- UAL 13.06
- NTRA N/A
- EPS
- UAL 9.98
- NTRA N/A
- Revenue
- UAL $57,986,000,000.00
- NTRA $1,964,250,000.00
- Revenue This Year
- UAL $4.43
- NTRA $23.93
- Revenue Next Year
- UAL $7.57
- NTRA $15.60
- P/E Ratio
- UAL $10.68
- NTRA N/A
- Revenue Growth
- UAL 4.23
- NTRA 44.38
- 52 Week Low
- UAL $44.57
- NTRA $110.57
- 52 Week High
- UAL $116.00
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- UAL 70.03
- NTRA 62.59
- Support Level
- UAL $101.75
- NTRA $156.71
- Resistance Level
- UAL $109.69
- NTRA $170.72
- Average True Range (ATR)
- UAL 2.97
- NTRA 4.62
- MACD
- UAL 0.06
- NTRA 0.39
- Stochastic Oscillator
- UAL 76.23
- NTRA 80.73
About UAL United Airlines Holdings Inc.
United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large US peers.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.